Printer Friendly

A Case of Recurrent Esophageal Cancer Treated with Concurrent Chemoradiation Therapy in Pregnancy.

1. Introduction

With increasing maternal age and improvements in diagnostic techniques, the incidence of cancer in pregnancy has risen to one in 1,000 pregnancies [1], and it is not necessarily a rare entity. However, esophageal cancer complicated with pregnancy is extremely uncommon. Thus, its management strategy has not yet been discussed thoroughly. Here, we describe a case of recurrent esophageal cancer treated successfully with concurrent chemoradiation therapy (CRT) during pregnancy. Further, we also review previously reported cases of esophageal cancer in pregnancy.

2. Case Report

A 41-year-old woman, gravida 2, para 1, was diagnosed with esophageal cancer relapse at 16 weeks of gestation. At the age of 40, before this spontaneous conception, she underwent preoperative chemotherapy, minimally invasive esophagectomy, and postoperative chemotherapy for esophageal squamous cell cancer, cStagell, pStagelV. Since the postoperative chemotherapy, she had been amenorrhoeic. Ten months after the operation, contrast enhanced computed tomography (CT) of the neck, chest, and abdominal to pelvis region was performed to investigate recurrence or metastasis, and it showed a pregnant uterus. She visited our obstetric clinic and was confirmed to be at 8 weeks of gestation. Because the estimated fetal exposure dose of the CT examination was less than 8 mGy, she wished to continue the pregnancy. At 16 weeks of gestation, the scheduled gastrointestinal endoscopy and biopsy revealed relapse of esophageal cancer in the residual esophagus (Figure 1). The fluorine-18 fluorodeoxyglucose (18F-FDG) uptake of the local recurrence in the residual esophagus was elevated according to positron emission tomography (PET)/CT, and no metastatic lesion was detected. A multidisciplinary treatment team consisting of medical oncologists, radiation oncologists, surgeons, and obstetricians recommended that the patient terminate the pregnancy and receive CRT, which was the standard treatment for localized recurrent disease [2, 3]. However, the patient and her husband strongly desired to continue the pregnancy.

To examine the safety and feasibility of radiotherapy for this patient, the fetal dose was estimated by a simulation study before CRT. We created the irradiation plan for the patient (Figure 2(a)) and delivered doses to the phantom (Figure 2(b)). According to the radiation dosage measured by five dosimeters, which ranged from 0.052 to 0.176 mGy in one irradiation fraction (Figure 2(c)), the fetal dose was estimated as 1.56 to 5.28 mGy, even after 60 Gy in 30 fractions of radiotherapy. The anticancer drugs, which would be administered together with the radiation, were cisplatin (CDDP) and 5-fluorouracil (5-FU). Taking these results, we concluded that CRT during pregnancy in this case would be acceptable and, after receiving written informed consent, started the treatment at 19 weeks of gestation.

The CRT consisted of 50.4 Gy in 28 fractions of radiation and four courses of chemotherapy (CDDP 60 mg/[m.sup.2] on day 1, 5-FU 750 mg/[m.sup.2] on days 1 to 4). Figure 3 shows the course of treatment over time. As supportive therapy, palonosetron and dexamethasone were administered. To assess the actual fetal dose of radiotherapy, we put dosimeters on the patient's abdomen at every irradiation session. Dosimeters showed that the estimated fetal dose ranged from 0.08 to 0.34 mGy in one irradiation fraction. Consequently, the multidisciplinary team confirmed the safety and feasibility of radiotherapy for this pregnant patient and fetus and completed the planned radiotherapy. After chemoradiotherapy, at 27 weeks of gestation, the recurrent lesion was decreased in size. Furthermore, gastrointestinal endoscopy at 31 weeks did not detect the recurrent lesion after the third course of chemotherapy. During this treatment, the myelosuppression was mild; grade 2 anemia, grade 1 neutrophil count decreased, and grade 1 platelet count decreased, according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The patient had also pharyngitis, anorexia, and vomiting. Regarding body habitus, her height was 162 cm, and her weight was 51 kg before the esophagectomy. Then she had lost 6 kg and her body mass index was 17.5 by the time she got pregnant. Her weight gain was only 3.9 kg during pregnancy because of impaired oral intake due to gastric tube reconstruction as well as adverse effect of CRT such as anorexia. The fetal estimated body weight fluctuated between the 10th and 20th percentile. Fetal well-being was monitored using ultrasound and nonstress fetal heart rate testing, and no abnormal findings were detected. At 38 weeks and 3 days of gestation, she underwent cesarean section (due to previous cesarean section) and gave birth to a female baby weighing 2,480 g. Apgar scores were 7 at 1 minute and 8 at 5 minutes, and the pH of umbilical artery blood was 7.327. The baby did not have any congenital anomalies, and the clinical course was uneventful. Twelve months have passed since the cesarean section, the patient has been free of disease, and the growth of the infant has been satisfactory.

3. Discussion

Esophageal cancer in pregnancy is extremely rare, because esophageal cancer occurs mainly in males in their sixties and seventies. There have been only five cases of esophageal cancer in pregnancy [4-8] thus far, as shown in Table 1. Four cases were primary esophageal cancer diagnosed in toon average, and the initial symptom was dysphagia in all cases. The prognosis of these cases was poor due to the aggressive nature of esophageal cancer. In the present case, however, recurrence was detected early as the localized disease by our regular trimonthly follow-up, and both maternal and fetal outcomes were favorable, while the median survival duration of the patients with recurrent disease after radical esophagectomy is 5 to 10 months [9].

When cancer is detected in pregnancy, especially before 22 weeks of gestation, both the patient and physicians are caught in a dilemma of whether to continue or terminate the pregnancy. In general, therapeutic strategies for cancer in pregnancy should adhere to the standard for nonpregnant patients, and treatment intensity should not be reduced to guard against potential adverse effects to the fetus. In the present case, because the patient and her husband strongly wished to continue the pregnancy, the multidisciplinary team assessed the feasibility of treatment during pregnancy. In order to permit the pregnancy continuation, it is essential to confirm no metastasis, and the patient underwent PET/CT. A full PET/CT scan is thought to deliver no greater than 15-20 mGy, and the placenta concentrates 0.19-0.27% of injected activity of 18F-FDG [10,11]. In general, the dose of 18F-FDG and radiation is reduced as much as possible for pregnant women to lessen fetal exposure. Indeed, in the present case, the estimated maternal radiation dosage by PET/CT was calculated to be 3.8 mSv; PET 2.1 mSv, and CT 1.7 mSv, which was approximately equal to 3.8 mGy. Accordingly, PET/CT during pregnancy might be allowed, given that PET/CT plays a pivotal role in diagnosis and surveillance of metastatic lesions.

It is acknowledged that cancer chemotherapy is possible after 12 to 14 weeks of gestation, which is the period of organogenesis [12]. Cisplatin and fluorouracil are key drugs for chemotherapy in esophageal cancer [13,14], and both have a relatively extensive history of use in pregnant patients from the second trimester onward. Mir et al. reported that, among 36 patients receiving cisplatin, one case of polyhydramnios, two cases of oligohydramnios, and three cases of fetal growth restriction were detected, although the causative link between cisplatin administration and these malformations remains speculative [15]. For 5-fluorouracil, one cohort study including 57 breast cancer patients receiving 5-fluorouracil during the second and third trimesters of pregnancy described three cases of congenital disease, including trisomy 21, club foot, and bilateral ureteral reflux [16]. The causal relationship between these diseases and 5-fluorouracil is unknown.

In our case, the newborn was relatively small at 2,480 g (13.2 percentile), although she was not regarded as small-for-gestational-age (SGA). It remains inconclusive whether cancer chemotherapy or cancer per se in pregnancy affects fetal growth. Cardonick et al. analyzed 376 fetuses exposed to chemotherapy in utero and reported that the incidence of fetal growth restriction was 7%, which might be as low as that in the normal population [17]. However, Van Calsteren et al. showed that SGA was observed significantly more often (16/66, 24.2%) in cancer patients given cytotoxic treatment [18]. Presumably, in the present case, CRT-induced pharyngitis and anorexia caused poor maternal weight gain during pregnancy, thereby contributing to the relatively light body weight of the newborn.

Meanwhile, radiotherapy during pregnancy could also be acceptable when the irradiation area is remote from the pelvis; several kinds of malignancies, such as breast cancer, Hodgkin's disease, brain tumors, and head and neck cancer, are treated with radiation therapy during pregnancy [19]. However, careful planning and calculation of the fetal dose using a phantom before treatment are necessary in order to assess the risk of radiation to the fetus. To evaluate and estimate the fetal dose, the Monte Carlo method can be employed. Bednarz and Xu demonstrated the computational procedure which could determine the absorbed organ dose in the mother and fetus, using realistic models of pregnant women during 3-, 6-, and 9-month gestational age [20]. In the current case, fetal dose was estimated at most 5.28 mGy even after 60 Gy in 30 fractions of radiotherapy. It was under the threshold dose for deterministic effects (50 mGy) regarding radiation injury to an unborn fetus [21]. Although the number of cases of chemotherapy and radiotherapy in pregnancy has been accumulating, CRT during pregnancy is still rare. To our knowledge, there has been no systematic review or cohort study verifying the adverse effects of CRT in pregnancy on the unborn fetus. Only in the fields of tongue cancer and Hodgkin's disease have a few cases of CRT in pregnancy been reported, and its influence on babies is currently unknown [22-24].

In summary, this is the first case of recurrent esophageal cancer in pregnancy in which CRT was completed without reducing treatment intensity and led to a complete response. Moreover, severe perinatal complications were not detected, and both the maternal and fetal courses were satisfactory. Our case suggests that CRT based on careful simulation could be an effective alternative treatment strategy for recurrent esophageal cancer in pregnancy. Nevertheless, little is known in terms of the safety and possible adverse effects of CRT on the fetus. Therefore, deliberate selection of patients and long-term follow-up of the child are necessary.


Written informed consent was obtained from the patient for the publication of this case report and its accompanying images.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.


[1] N. A. Pavlidis, "Coexistence of pregnancy and malignancy," The Oncologist, vol. 7, no. 4, pp. 279-287, 2002.

[2] J. S. Cooper, M. D. Guo, A. Herskovic et al., "Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)," Journal of the American Medical Association, vol. 281, no. 17, pp. 1623-1627, 1999.

[3] B. D. Minsky, T. F. Pajak, R. J. Ginsberg et al., "INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy," Journal of Clinical Oncology, vol. 20, no. 5, pp. 1167-1174, 2002.

[4] Z. Akdemir, "A case of metastatic esophageal carcinoma in a pregnant woman with radiologic findings," Journal of Clinical and Diagnostic Research, vol. 10, no. 1, 2016.

[5] I. Al-Githmi, "Esophageal cancer associated with pregnancy," Journal of Obstetrics and Gynaecology Canada, vol. 31, no. 8, pp. 730-731, 2009.

[6] A. P. Jain, A. A. Patel, A. S. Anand, and S. A. Shah, "Esophageal carcinoma in pregnancy," The Journal of Obstetrics and Gynecology of India, vol. 64, no. S1, pp. 53-54, 2014.

[7] M. Sahin, G. Kocaman, M. Ozkan, C. Yuksel, S. Enon, and H. Kutlay, "Resection of esophageal carcinoma during pregnancy," The Annals of Thoracic Surgery, vol. 99, no. 1, pp. 333-335,2015.

[8] J. B. Sharma, P. Gupta, S. Kumar, K. K. Roy, N. Malhotra, and T. K. Chattopadhyay, "Esophageal carcinoma during pregnancy: a case report," Archives of Gynecology and Obstetrics, vol. 279, no. 3, pp. 401-402, 2009.

[9] Y. Kitagawa, T. Uno, T. Oyama et al., "Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2," Esophagus, 2018.

[10] P. Zanotti-Fregonara, S. Jan, C. Champion et al., "In vivo quantification of 18F-FDG uptake in human placenta during early pregnancy," Health Physics Journal, vol. 97, no. 1, pp. 82-85, 2009.

[11] P. Zanotti-Fregonara, R. Laforest, and J. W. Wallis, "Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR," Journal of Nuclear Medicine, vol. 56, no. 8, pp. 1218-1222, 2015.

[12] F. Amant et al., "Management of cancer in pregnancy," Best Practice & Research: Clinical Obstetrics & Gynaecology, vol. 29, no. 5, pp. 741-753, 2015.

[13] T. Conroy, M.-P. Galais, J.-L. Raoul et al., "Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial," The Lancet Oncology, vol. 15, no. 3, pp. 305-314, 2014.

[14] J. Honing, J. K. Smit, C. T. Muijs et al., "A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients," Annals of Oncology, vol. 25, no. 3, Article ID mdt589, pp. 638-643, 2014.

[15] O. Mir, P. Berveiller, S. Ropert, F. Goffinet, and F. Goldwasser, "Use ofplatinum derivatives during pregnancy," Cancer, vol. 113, no. 11, pp. 3069-3074, 2008.

[16] K. M. E. Hahn, P. H. Johnson, N. Gordon et al., "Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero," Cancer, vol. 107, no. 6, pp. 1219-1226, 2006.

[17] E. Cardonick and A. Iacobucci, "Use of chemotherapy during human pregnancy," The Lancet Oncology, vol. 5, no. 5, pp. 283-291, 2004.

[18] K. Van Calsteren, L. Heyns, F. De Smet et al., "Cancer during pregnancy: An analysis of 215 patients emphasizing the obstetrical and the Neonatal outcomes," Journal of Clinical Oncology, vol. 28, no. 4, pp. 683-689, 2010.

[19] H. B. Kal and H. Struikmans, "Radiotherapy during pregnancy: fact and fiction," The Lancet Oncology, vol. 6, no. 5, pp. 328-333, 2005.

[20] B. Bednarz and X. G. Xu, "A feasibility study to calculate unshielded fetal doses to pregnant patients in 6-MV photon treatments using Monte Carlo methods and anatomically realistic phantoms," Medical Physics, vol. 35, no. 7, pp. 3054-3061, 2008.

[21] P. International Commission on Radiological, "Pregnancy and medical radiation," in Proceedings of the Ann ICRP, vol. 30, pp. 1-43, 2000.

[22] M. Lishner, D. Zemlickis, P. Degendorfer, T. Panzarella, S. Sutcliffe, and G. Koren, "Maternal and foetal outcome following Hodgkin's disease in pregnancy," British Journal of Cancer, vol. 65, no. 1, pp. 114-117, 1992.

[23] M. M. Gziri, S. N. Han, K. Van Calsteren et al., "Tongue cancers during pregnancy: Case reports and review of literature," Head & Neck, vol. 35, no. 4, pp. E102-E108, 2013.

[24] J. Murphy, D. R. Berman, S. P. Edwards, J. Prisciandaro, A. Eisbruch, and B. B. Ward, "Squamous cell carcinoma of the tongue during pregnancy: a case report and review of the literature," Journal ofOral and Maxillofacial Surgery, vol. 74, no. 12, pp. 2557-2566,2016.

Kaori Yamada, (1) Yoshitsugu Chigusa (iD), (1) Motoo Nomura, (2) Katsuyuki Sakanaka, (3) Mitsuhiro Nakamura, (3,4) Shinsuke Yano, (5) Shigeru Tsunoda, (6) Eiji Kondoh, (1) and Masaki Mandai (1)

(1) Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

(2) Department of Therapeutic Oncology, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

(3) Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

(4) Division of Medical Physics, Department of Information Technology and Medical Engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

(5) Division of Clinical Radiology Service, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

(6) Department of Surgery, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Correspondence should be addressed to Yoshitsugu Chigusa;

Received 9 October 2018; Revised 14 November 2018; Accepted 22 November 2018; Published 3 December 2018

Academic Editor: Yoshio Yoshida

Caption: Figure 1: The gastrointestinal endoscopic finding at 16 weeks of gestation. Arrowheads indicate the recurrent lesion of esophageal cancer in the residual esophagus.

Caption: Figure 3: The time course of treatment. The horizontal axis indicates gestational weeks. CF, cisplatin 60 mg/[m.sup.2], 5-fluorouracil 750 mg/[m.sup.2]; CS, cesarean section.
Table 1: Cases of esophageal cancer during pregnancy
reported in the literature.

                        Primary      (weeks
                          or           of
Case             Age   recurrence   gestation)    symptoms

Sharma et        36     Primary         29       dysphagia,
al. 2009                                         hematemesis
Al-Githmi et     29     Primary         29       dysphagia,
al. 2009                                         weight loss
Jain et          27    Recurrence       26       dysphagia,
al. 2014                                         weight loss
Sahin et         26     Primary         27       dysphagia,
al. 2015                                         weight loss
Akdemir et       39     Primary         28       dysphagia,
al. 2016                                         weight loss
The present      41    Recurrence       16          none

                                        of          Fetal
Case                 Treatment       gestation)    outcome

Sharma et         Surgery after        31 CS       2,200 g
al. 2009             delivery                     uneventful
Al-Githmi et      Surgery after        32 CS       unknown
al. 2009             delivery
Jain et            Chemotherapy        34 CS       2,300 g
al. 2014         during pregnancy                 uneventful
Sahin et          Surgery during       32 VD      uneventful
al. 2015             pregnancy
Akdemir et          Refusal of         34 CS       2,650 g
al. 2016             treatment                    uneventful
The present         CRT during         38 CS       2,480 g
case                 pregnancy                    uneventful

Case              outcome

Sharma et          Death
al. 2009
Al-Githmi et       Death
al. 2009
Jain et          Survival
al. 2014
Sahin et         Survival
al. 2015
Akdemir et        Unknown
al. 2016
The present      Survival

CRT, concurrent chemoradiation therapy; CS, cesarean section;
VD, vaginal delivery.

Figure 2: The simulation study of radiotherapy using a phantom. (a)
The irradiation plan was created based on the recurrent lesion. The
distance between the inferior margin of irradiation and the uterine
fundus was 38 cm. (b) Five dosimeters (arrows) were put on the
phantom's abdomen. (c) The radiation dosage measured by five
dosimeters in one irradiation fraction.

dosimeters      radiation dosage (mGy)

A                      0.176
B                      0.174
C                      0.096
D                      0.065
E                      0.052
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Case Report
Author:Yamada, Kaori; Chigusa, Yoshitsugu; Nomura, Motoo; Sakanaka, Katsuyuki; Nakamura, Mitsuhiro; Yano, S
Publication:Case Reports in Obstetrics and Gynecology
Geographic Code:9JAPA
Date:Jan 1, 2018
Previous Article:Spontaneous Ruptured Pyomyoma in a Nulligravid Female: A Case Report and Review of the Literature.
Next Article:Mirror Syndrome in Monochorionic Twin Pregnancy with Acardiac Fetus.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters